Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 18/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11592550 | 1.00 | IL23R (0.61) | IL23RPRMT1 | |
| SCHEMBL11592493 | 1.00 | IL23R (0.61) | IL23RPRMT1 | |
| SCHEMBL27602608 | 1.00 | IL23R (0.61) | IL23RPRMT1 | |
| SCHEMBL27602616 | 1.00 | IL23R (0.61) | IL23RPRMT1 | |
| SCHEMBL11578176 | 0.98 | IL23R (0.59) | IL23RPRMT1 | |
| SCHEMBL11881751 | 0.98 | IL23R (0.63) | IL23R | |
| SCHEMBL11881838 | 0.98 | IL23R (0.63) | IL23R | |
| SCHEMBL29367373 | 0.96 | IL23R (0.64) | IL23R | |
| SCHEMBL11593966 | 0.96 | IL23R (0.62) | IL23RPRMT1 | |
| SCHEMBL11593910 | 0.96 | IL23R (0.62) | IL23RPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867864-B2 | Use of somatostatin analogs in control of hypoglycemia | NOVARTIS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160184388-A1 | Use of Somatostatin Analogs in Control of Hypoglycemia | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-9149510-B2 | Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes | NOVARTIS AG (SE) | 2015-10-06 | — | — | US | disclosed |
| US-20140235555-A1 | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20130237480-A1 | COMBINATIONS OF SOMATOSTATIN-ANALOGS WITH DIFFERENT SELECTIVITY FOR HUMAN SOMATOSTATIN RECEPTOR SUBTYPES | NOVARTIS AG (CH) | 2013-09-12 | — | — | US | disclosed |
| US-20130116178-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS | NOVARTIS AG (CH) | 2013-05-09 | — | — | US | disclosed |
| US-20120214749-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20110319329-A1 | USE OF SOMATOSTATIN ANALOGS IN CLUSTER HEADACHE | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319329-A1 | USE OF SOMATOSTATIN ANALOGS IN CLUSTER HEADACHE | SSTR3, SSTR2, SSTR1 | IL23R 888/4885PRMT1 3501/4885 |
| US-20120214749-A1 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES | SSTR5, SSTR3, SSTR4 | IL23R 2518/4885PRMT1 2679/4885 |
| US-20130237480-A1 | COMBINATIONS OF SOMATOSTATIN-ANALOGS WITH DIFFERENT SELECTIVITY FOR HUMAN SOMATOSTATIN RECEPTOR SUBTYPES | SSTR3, SSTR5, SSTR4 | IL23R 362/4885PRMT1 2209/4885 |
| US-20140235555-A1 | Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons | PGM2, PLG, RPL7 | IL23R 434/4885PRMT1 4698/4885 |
| US-20160184388-A1 | Use of Somatostatin Analogs in Control of Hypoglycemia | SSTR3, SSTR5, SSTR1 | IL23R 1143/4885PRMT1 3098/4885 |
| US-20130116178-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS | PGM2, PLG, RPL7 | IL23R 322/4885PRMT1 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.